IRIS Accounts Production v25.3.0.601 13512661 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 13512661 2024-03-31 13512661 2025-03-31 13512661 2024-04-01 2025-03-31 13512661 2023-03-31 13512661 2023-04-01 2024-03-31 13512661 2024-03-31 13512661 ns15:EnglandWales 2024-04-01 2025-03-31 13512661 ns14:PoundSterling 2024-04-01 2025-03-31 13512661 ns10:Director1 2024-04-01 2025-03-31 13512661 ns10:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 13512661 ns10:SmallEntities 2024-04-01 2025-03-31 13512661 ns10:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 13512661 ns10:SmallCompaniesRegimeForDirectorsReport 2024-04-01 2025-03-31 13512661 ns10:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 13512661 ns10:FullAccounts 2024-04-01 2025-03-31 13512661 ns10:Director2 2024-04-01 2025-03-31 13512661 ns10:Director3 2024-04-01 2025-03-31 13512661 ns10:RegisteredOffice 2024-04-01 2025-03-31 13512661 ns5:CurrentFinancialInstruments 2025-03-31 13512661 ns5:CurrentFinancialInstruments 2024-03-31 13512661 ns5:Non-currentFinancialInstruments 2025-03-31 13512661 ns5:Non-currentFinancialInstruments 2024-03-31 13512661 ns5:ShareCapital 2025-03-31 13512661 ns5:ShareCapital 2024-03-31 13512661 ns5:SharePremium 2025-03-31 13512661 ns5:SharePremium 2024-03-31 13512661 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 13512661 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 13512661 ns5:CostValuation 2024-03-31 13512661 ns5:AdditionsToInvestments 2025-03-31 13512661 ns5:CostValuation 2025-03-31 13512661 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-03-31 13512661 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-03-31 13512661 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 13512661 ns5:SharePremium 2024-03-31 13512661 ns5:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31 13512661 1 2024-04-01 2025-03-31

REGISTERED NUMBER: 13512661 (England and Wales)

| NEUROCHASE HOLDINGS LIMITED |

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 31 MARCH 2025 |

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

NEUROCHASE HOLDINGS LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 31 MARCH 2025

| DIRECTORS: | Prof S S Gill

| Mrs S Kane

| Mr K D Murdoch

| REGISTERED OFFICE: | St Brandon's House

| 29 Great George Street

| Bristol

| BS1 5QT

| REGISTERED NUMBER: | 13512661 (England and Wales)

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

BALANCE SHEET

31 MARCH 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Investments | 4 | 201 |  | 101 |  |

CURRENT ASSETS

Debtors | 5 | 973,215 |  | 164,342 |  |

Cash at bank | 15,446 |  | 1,425 |  |

988,661 |  | 165,767 |  |

CREDITORS

Amounts falling due within one year | 6 | 3,904 |  | 2,098 |  |

NET CURRENT ASSETS | 984,757 |  | 163,669 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 984,958 |  | 163,770 |  |

CREDITORS

Amounts falling due after more than one year | 7 | 853,605 |  | - |  |

NET ASSETS | 131,353 |  | 163,770 |  |

CAPITAL AND RESERVES

Called up share capital | 8 | 1 |  | 1 |  |

Share premium | 9 | 200,000 |  | 200,000 |  |

Retained earnings | 9 | (68,648 | ) | (36,231 | ) |

SHAREHOLDERS' FUNDS | 131,353 |  | 163,770 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

BALANCE SHEET - continued

31 MARCH 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 22 October 2025 and were signed on its behalf by:

Mrs S Kane - Director

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

1. | STATUTORY INFORMATION

| Neurochase Holdings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Going concern

| The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. In making their assessment, the directors have reviewed the balance sheet, the likely future cash flows of the business and have considered the facilities that are available to the company along with their continued support.

| At the date of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and that the going concern basis of accounting remains appropriate.

| Subsequent to the year end, the company completed an equity funding round which further supports the directors' assessment that the company has adequate resources to continue in operational existence for the foreseeable future.

| The directors therefore continue to adopt the going concern basis of accounting in preparing the financial statements.

| Preparation of consolidated financial statements

| The financial statements contain information about Neurochase Holdings Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

| Significant judgements and estimates

| In the application of the company's accounting policies, which are described in note 2, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2025

2. | ACCOUNTING POLICIES - continued

| Investments in subsidiaries

| The company has adopted the cost model in recognising and remeasuring investments in associates. Investments in associates are recognised at cost less any accumulated impairment losses.

| Dividends or other distributions received from the associated company are recognised in the income statement during the period which it relates too.

| Cash & cash equivalents

| Cash and cash equivalents are basic financial instruments and include cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

| Financial instruments

| The company has elected to apply the provisions of Section 11 "Basic Financial Instruments".

| Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

| Basic financial assets

| Basic financial assets, which include trade and other debtors, loans to related companies and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

| Basic financial liabilities

| Basic financial liabilities, including trade and other creditors, loans to related companies and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Impairment

| Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the assets cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2025

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 3 (2024 - 3 ) .

4. | FIXED ASSET INVESTMENTS

| Shares in

| group

| undertakings

£ |

| COST

| At 1 April 2024 | 101 |  |

| Additions | 100 |  |

| At 31 March 2025 | 201 |  |

| NET BOOK VALUE

| At 31 March 2025 | 201 |  |

| At 31 March 2024 | 101 |  |

| At the balance sheet date, the company held interests in the following subsidiaries:

|  | Proportion of |  | Nature of |  |

| Name of Subsidiary |  | Country of Incorporation |  | Shares Held |  | Business |  |

| Neurochase Technologies Ltd |  | England and Wales |  | 100% |  | IP Leasing |  |

| Neurochase Innovations Ltd |  | England and Wales |  | 100% |  | IP Leasing |  |

| Neurochase Ltd |  | England and Wales |  | 100% |  | Research and |  |

| experimental |  |

|  | development of |  |

|  | biotechnolog y |  |

| The investments in the above subsidiaries are held at cost.

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Amounts owed by group undertakings | 973,215 |  | 163,215 |  |

| Other debtors | - |  | 1,127 |  |

973,215 |  | 164,342 |  |

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2025

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Taxation and social security | 1,904 |  | 599 |  |

| Other creditors | 2,000 |  | 1,499 |  |

3,904 |  | 2,098 |  |

7. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Other creditors | 853,605 |  | - |  |

8. | CALLED UP SHARE CAPITAL

| Number: |  | Class: |  | Nominal value: |  | £ |  |

| 510 |  | Ordinary A shares |  | 0.001 |  | 0.51 |  |

| 190 |  | Ordinary B shares |  | 0.001 |  | 0.19 |  |

| 250 |  | Ordinary C shares |  | 0.001 |  | 0.25 |  |

| 50 |  | Ordinary D shares |  | 0.001 |  | 0.05 |  |

| 10 |  | Ordinary E shares |  | 0.001 |  | 0.01 |  |

|  | 1.01 |  |

9. | RESERVES

| Retained |  | Share |

| earnings |  | premium |  | Totals

£ | £ | £ |

| At 1 April 2024 | (36,231 | ) | 200,000 |  | 163,769 |  |

| Deficit for the year | (32,417 | ) | (32,417 | ) |

| At 31 March 2025 | (68,648 | ) | 200,000 |  | 131,352 |  |

10. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| On 16 August 2024, Neurochase Holdings Limited completed the acquisition of the remaining share capital of Neurochase Innovations Limited and Neurochase Technologies Limited, thereby making them wholly-owned subsidiaries of Neurochase Holdings Limited.

NEUROCHASE HOLDINGS LIMITED (REGISTERED NUMBER: 13512661)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 MARCH 2025

11. | POST BALANCE SHEET EVENTS

| On 22 April 2025, after the company's year end, Neurochase Holdings Limited completed an equity funding round of £6 million. This investment will be used to support the continued development and operations of its key trading subsidiary, Neurochase Limited, and other Group companies.

| As this event occurred after the balance sheet date of 31 March 2025, it is treated as a non-adjusting post balance sheet event. Accordingly, it does not affect the figures reported in these financial statements.

12. | ULTIMATE CONTROLLING PARTY

| The controlling party is Professor Steven Gill.